A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms

Vitamin D is a fat-soluble secosteroid that exerts its effects by binding to the vitamin D receptor (VDR), through which it directly and indirectly modulates the expression of hundreds to thousands of genes. While originally known for its role in regulating calcium homeostasis and metabolism, vitamin D is now associated with many other health conditions, including Parkinson's disease (PD). A high prevalence of vitamin D deficiency has been noted in PD for at least the past two decades. These findings, along with the discovery that the VDR and 1α-hydroxylase, the enzyme that converts vitamin D to its active form, are highly expressed in the substantia nigra, led to the hypothesis that inadequate levels of circulating vitamin D may lead to dysfunction or cell death within the substantia nigra. Studies investigating the relationship between vitamin D status and PD, however, have been inconsistent. Two prospective studies examined the association between mid-life vitamin D levels and risk of PD and produced conflicting results—one demonstrated an increased risk for PD with lower mid-life vitamin D levels, and the other showed no association between vitamin D and PD risk. One of the most consistent findings in the literature is the inverse association between serum vitamin D level and motor symptom severity in cross-sectional studies. While these data suggest that vitamin D may modify the disease, another likely explanation is confounding due to limited mobility. Fall risk has been associated with vitamin D in PD, but more study is needed to determine if supplementation decreases falls, which has been demonstrated in the general population. The association between vitamin D and non-motor symptoms is less clear. There is some evidence that vitamin D is associated with verbal fluency and verbal memory in PD. Studies in PD have also shown associations between vitamin D status and mood, orthostatic hypotension and olfactory impairment in PD. While more research is needed, given the numerous potential benefits and limited risks, vitamin D level assessment in PD patients and supplementation for those with deficiency and insufficiency seems justified.

[1]  N. Yılmaz,et al.  Nocturnal blood pressure changes in Parkinson's disease: correlation with autonomic dysfunction and vitamin D levels. , 2020 .

[2]  M. Holick,et al.  Variable Genomic and Metabolomic Responses to Varying Doses of Vitamin D Supplementation , 2020, AntiCancer Research.

[3]  Y. Ben-Shlomo,et al.  Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort , 2019, Movement disorders : official journal of the Movement Disorder Society.

[4]  C. Mao,et al.  Relationship between 25‐Hydroxyvitamin D, bone density, and Parkinson’s disease symptoms , 2019, Acta neurologica Scandinavica.

[5]  K. Michaëlsson,et al.  [Bisphosphonate-associated atypical fractures of the femur: an update of the current evidence]. , 2019, Lakartidningen.

[6]  R. Kenny,et al.  Vitamin D Status Is Not Associated With Orthostatic Hypotension in Older Adults. , 2019, Hypertension.

[7]  D. Lehrer,et al.  Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  N. Shen,et al.  Vitamin D receptor polymorphisms and the susceptibility of Parkinson’s disease , 2019, Neuroscience Letters.

[9]  Ji Sun Kim,et al.  Serum 25-hydroxyvitamin D3 level may be associated with olfactory dysfunction in de novo Parkinson's disease , 2018, Journal of Clinical Neuroscience.

[10]  C. Christine,et al.  Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson’s disease , 2018, Journal of Clinical Movement Disorders.

[11]  J. Quinn,et al.  A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter? , 2018, PloS one.

[12]  G. Shahidi,et al.  Treatment of Levodopainduced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial , 2018, Neurology international.

[13]  X. Fang,et al.  Association of Levels of Physical Activity With Risk of Parkinson Disease , 2018, JAMA network open.

[14]  Jun Xu,et al.  Postnatal Vitamin D Intake Modulates Hippocampal Learning and Memory in Adult Mice , 2018, Front. Neurosci..

[15]  M. Krasowski,et al.  Vitamin D Toxicity: A 16-Year Retrospective Study at an Academic Medical Center , 2018, Laboratory medicine.

[16]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[17]  D. Jennings,et al.  Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study , 2017, Movement disorders : official journal of the Movement Disorder Society.

[18]  D. Burn,et al.  The Role of Vitamin D in Disease Progression in Early Parkinson’s Disease , 2017, Journal of Parkinson's disease.

[19]  Lynette M. Smith,et al.  Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  P. Mumby,et al.  Vitamin D Supplementation Improves Mood in Women with Type 2 Diabetes , 2017, Journal of diabetes research.

[21]  M. Nalls,et al.  No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study , 2017, Movement disorders : official journal of the Movement Disorder Society.

[22]  J. Sinsheimer,et al.  Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease , 2016, Journal of the Neurological Sciences.

[23]  A. Ascherio,et al.  The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.

[24]  Marjan Jahanshahi,et al.  Postural instability and falls in Parkinson’s disease , 2016, Reviews in the neurosciences.

[25]  Xuemei Huang,et al.  Serum 25‐hydroxyvitamin D concentrations in Mid‐adulthood and Parkinson's disease risk , 2016, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Abbott,et al.  Serum vitamin D and risk of Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[27]  D. Burn,et al.  Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association? , 2016, Movement disorders : official journal of the Movement Disorder Society.

[28]  S. Akdeniz,et al.  The relation between vitamin D and postural balance according to clinical tests and tetrax posturography , 2016, Journal of physical therapy science.

[29]  J. Toledo,et al.  Olfactory impairment predicts cognitive decline in early Parkinson's disease. , 2016, Parkinsonism & related disorders.

[30]  G. Sergi,et al.  Hypovitaminosis D and orthostatic hypotension: a systematic review and meta-analysis , 2016, Journal of hypertension.

[31]  W. Willett,et al.  Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial. , 2016, JAMA internal medicine.

[32]  J. Youn,et al.  Vitamin D deficiency in Parkinson's disease patients with orthostatic hypotension , 2015, Acta neurologica Scandinavica.

[33]  A. Xie,et al.  ApaI, BsmI, FokI, and TaqI Polymorphisms in the Vitamin D Receptor Gene and Parkinson's Disease , 2015, Chinese medical journal.

[34]  L. Bour,et al.  The PowerGlove: Assessment of hand and finger movements in Parkinson’s disease patients , 2015 .

[35]  C. Annweiler,et al.  Vitamin D Deficiency and Incident Onset of Orthostatic Hypotension in Older Adults: Preliminary Results from the ‘MERE’ Study , 2015, Journal of the American Geriatrics Society.

[36]  Shuqin Wei,et al.  Vitamin D receptor gene polymorphisms and the risk of Parkinson’s disease , 2015, Neurological Sciences.

[37]  Gui-you Liu,et al.  Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson’s disease , 2014, Journal of Zhejiang University SCIENCE B.

[38]  G. Sergi,et al.  Serum 25-Hydroxyvitamin D and Orthostatic Hypotension in Old People: The Pro.V.A. Study , 2014, Hypertension.

[39]  C. Annweiler,et al.  Vitamin D deficiency is associated with orthostatic hypotension in oldest‐old women , 2014, Journal of internal medicine.

[40]  P. Donnan,et al.  Effect of vitamin D supplementation on orthostatic hypotension: data from the Vitamin D in Isolated Systolic Hypertension randomized controlled trial , 2014, Journal of hypertension.

[41]  Y. Lee,et al.  Vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease and Alzheimer’s disease: a meta-analysis , 2014, Neurological Sciences.

[42]  P. Soysal,et al.  Does vitamin D deficiency increase orthostatic hypotension risk in the elderly patients? , 2014, Archives of gerontology and geriatrics.

[43]  B. Bloem,et al.  Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. , 2014, Parkinsonism & related disorders.

[44]  J. Growdon,et al.  Unrecognized vitamin D3 deficiency is common in Parkinson disease , 2013, Neurology.

[45]  G. Ebers,et al.  Review: The role of vitamin D in nervous system health and disease , 2013, Neuropathology and applied neurobiology.

[46]  S. Yılmazer,et al.  Vitamin D inquiry in hippocampal neurons: consequences of vitamin D-VDR pathway disruption on calcium channel and the vitamin D requirement , 2013, Neurological Sciences.

[47]  M. Maracy,et al.  25-Hydroxyvitamin D and Severity of Parkinson's Disease , 2013, International journal of endocrinology.

[48]  F. Horak,et al.  The relationship between balance control and vitamin D in Parkinson's disease—a pilot study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[49]  Liang Shen,et al.  Vitamin D levels in Alzheimer's and Parkinson's diseases: a meta-analysis. , 2013, Nutrition.

[50]  M. Urashima,et al.  Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. , 2013, The American journal of clinical nutrition.

[51]  Natalie E. Allen,et al.  Recurrent Falls in Parkinson's Disease: A Systematic Review , 2013, Parkinson's disease.

[52]  Małgorzata Wrzosek,et al.  Vitamin D and the central nervous system , 2013, Pharmacological reports : PR.

[53]  S. Walter,et al.  Vitamin D deficiency and depression in adults: systematic review and meta-analysis , 2013, British Journal of Psychiatry.

[54]  J. Manson,et al.  Calcium and Vitamin D Supplementation and Cognitive Impairment in the Women's Health Initiative , 2012, Journal of the American Geriatrics Society.

[55]  R. Kenny,et al.  Vitamin D and orthostatic hypotension. , 2012, Age and ageing.

[56]  J. Kaye,et al.  Serum vitamin d concentrations are associated with falling and cognitive function in older adults , 2012, The journal of nutrition, health & aging.

[57]  C. Annweiler,et al.  Higher vitamin D dietary intake is associated with lower risk of alzheimer's disease: a 7-year follow-up. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[58]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[59]  M. Urashima,et al.  25‐hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[60]  D. Eyles,et al.  The effects of vitamin D on brain development and adult brain function , 2011, Molecular and Cellular Endocrinology.

[61]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[62]  R. Albin,et al.  The cholinergic system and Parkinson disease , 2011, Behavioural Brain Research.

[63]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[64]  J. Woo,et al.  Association between serum 25-hydroxyvitamin D and psychological health in older Chinese men in a cohort study. , 2011, Journal of affective disorders.

[65]  M. Cesari,et al.  Vitamin D hormone: A multitude of actions potentially influencing the physical function decline in older persons , 2011, Geriatrics & gerontology international.

[66]  M. Delong,et al.  High prevalence of hypovitaminosis D status in patients with early Parkinson disease. , 2011, Archives of neurology.

[67]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[68]  D. Melzer,et al.  Vitamin D and risk of cognitive decline in elderly persons. , 2010, Archives of internal medicine.

[69]  P. Knekt,et al.  Serum vitamin D and the risk of Parkinson disease. , 2010, Archives of neurology.

[70]  B. Horne,et al.  Association of vitamin D levels with incident depression among a general cardiovascular population. , 2010, American heart journal.

[71]  J. Simpson,et al.  Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. , 2010, JAMA.

[72]  C. Annweiler,et al.  Association of vitamin D deficiency with cognitive impairment in older women , 2010, Neurology.

[73]  O. Franco,et al.  Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese. , 2009, Journal of affective disorders.

[74]  J B Wong,et al.  Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[75]  I. Lang,et al.  Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment , 2009, Journal of geriatric psychiatry and neurology.

[76]  M. V. Magni,et al.  Effect of 1α,25‐dihydroxyvitamin D3 in embryonic hippocampal cells , 2009, Hippocampus.

[77]  H. Minne,et al.  Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals , 2009, Osteoporosis International.

[78]  J. Svartberg,et al.  Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial , 2008, Journal of internal medicine.

[79]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[80]  M. Khrestchatisky,et al.  Vitamin D2 potentiates axon regeneration. , 2008, Journal of neurotrauma.

[81]  H. Berendse,et al.  A comparative study of odor identification and odor discrimination deficits in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[82]  M. Delong,et al.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.

[83]  Tore Wentzel-Larsen,et al.  Predictors and course of health‐related quality of life in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[84]  S. Frings,et al.  Calcium-signaling networks in olfactory receptor neurons , 2008, Neuroscience.

[85]  D. Thurman,et al.  Evidence-based Review): Report of the Quality Standards Subcommittee of the Practice Parameter: Assessing Patients in a Neurology Practice for Risk of Falls (an , 2022 .

[86]  F. Schmidt Meta-Analysis , 2008 .

[87]  C. Cooper,et al.  Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. , 2007, Rheumatology.

[88]  Jonathan Newmark,et al.  Vitamin D and Parkinson's disease—A hypothesis , 2007, Movement disorders : official journal of the Movement Disorder Society.

[89]  Yvette I Sheline,et al.  Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[90]  G. Miller,et al.  Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor , 2006, Behavioural Brain Research.

[91]  W. Cass,et al.  Calcitriol Protection against Dopamine Loss Induced by Intracerebroventricular Administration of 6-Hydroxydopamine , 2006, Neurochemical Research.

[92]  John H. White,et al.  Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. , 2005, Molecular endocrinology.

[93]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[94]  S. Ingles,et al.  Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. , 2005, Cancer research.

[95]  A. Mackay-Sim,et al.  Behavioural characterization of Vitamin D receptor knockout mice , 2005, Behavioural Brain Research.

[96]  B. Hollis Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.

[97]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[98]  L. Bearne,et al.  Vitamin D supplementation improves neuromuscular function in older people who fall. , 2004, Age and ageing.

[99]  D. Burn,et al.  Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[100]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[101]  H. Berendse,et al.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.

[102]  Jeffrey M. Hausdorff,et al.  Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena , 2004, Movement disorders : official journal of the Movement Disorder Society.

[103]  Bess Dawson-Hughes,et al.  Effect of Vitamin D on falls: a meta-analysis. , 2004, JAMA.

[104]  H. Bischoff,et al.  Alfacalcidol Reduces the Number of Fallers in a Community‐Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily , 2004, Journal of the American Geriatrics Society.

[105]  Y-C Pai,et al.  Role of feedforward control of movement stability in reducing slip-related balance loss and falls among older adults. , 2003, Journal of neurophysiology.

[106]  D. Eyles,et al.  1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons , 2003, Neuroscience Letters.

[107]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[108]  R. Lew,et al.  Effects of Vitamin D and Calcium Supplementation on Falls: A Randomized Controlled Trial , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[109]  M. Tinetti Clinical practice. Preventing falls in elderly persons. , 2003, The New England journal of medicine.

[110]  R. Walker,et al.  Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[111]  Stephen H. D. Jackson,et al.  Neuromuscular and Psychomotor Function in Elderly Subjects Who Fall and the Relationship With Vitamin D Status , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[112]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[113]  B. Hoffer,et al.  Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats , 2001, Brain Research.

[114]  S. Shimohama,et al.  Protective effects of 1α,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture , 2001, Neuropharmacology.

[115]  J. P. Herman,et al.  Evidence of functional vitamin D receptors in rat hippocampus , 2001, Neuroscience.

[116]  K. Covinsky,et al.  History and mobility exam index to identify community-dwelling elderly persons at risk of falling. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[117]  Philip W. Landfield,et al.  Vitamin D Hormone Confers Neuroprotection in Parallel with Downregulation of L-Type Calcium Channel Expression in Hippocampal Neurons , 2001, The Journal of Neuroscience.

[118]  S. Kikuchi,et al.  Effect of 1,25‐dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L‐buthionine sulfoximine and 1‐methyl‐4‐phenylpyridine , 2000, Journal of neuroscience research.

[119]  Helena C. Kraemer,et al.  Risk factors and prevention , 2000 .

[120]  T. Hayashi,et al.  Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats , 2000, Neuropharmacology.

[121]  T. Veenstra,et al.  Distribution of 1,25-Dihydroxyvitamin D3 Receptor Immunoreactivity in the Rat Olfactory System , 1999, Cellular and Molecular Neurobiology.

[122]  M. Stein,et al.  Falls Relate to Vitamin D and Parathyroid Hormone in an Australian Nursing Home and Hostel , 1999, Journal of the American Geriatrics Society.

[123]  M. Miller,et al.  A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats , 1999, Diabetologia.

[124]  M. Kashiwagi,et al.  Regulation by 1α,25‐dihydroxyvitamin D3 of expression of stanniocalcin messages in the rat kidney and ovary , 1999, FEBS letters.

[125]  T. Veenstra,et al.  An AP-1 site in the nerve growth factor promoter is essential for 1, 25-dihydroxyvitamin D3-mediated nerve growth factor expression in osteoblasts. , 1998, Biochemistry.

[126]  Barrett T. Kitch,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[127]  P. Brachet,et al.  Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25‐dihydroxyvitamin D3 , 1998, Glia.

[128]  Yoshihiro Sato,et al.  High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease [RETRACTED] , 1997, Neurology.

[129]  O. Rascol,et al.  Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[130]  P. Rothwell,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[131]  P. Trouillas,et al.  Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[132]  P. Brachet,et al.  1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.

[133]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3, an inducer of glial cell line‐derived neurotrophic factor , 1996, Neuroreport.

[134]  G. Breart,et al.  Fall-related factors and risk of hip fracture: the EPIDOS prospective study , 1996, The Lancet.

[135]  H Kaufmann,et al.  Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy , 1996, Clinical Autonomic Research.

[136]  N. Alexander Gait Disorders in Older Adults , 1996, Journal of the American Geriatrics Society.

[137]  J. Tobin,et al.  Vitamin D Deficiency in Older People , 1995, Journal of the American Geriatrics Society.

[138]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3 regulates NT‐3, NT‐4 but not BDNF mRNA in astrocytes , 1994, Neuroreport.

[139]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[140]  R. Houlgatte,et al.  1,25‐Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis , 1991, Journal of neuroscience research.

[141]  S. Cummings,et al.  A hypothesis: the causes of hip fractures. , 1989, Journal of gerontology.

[142]  R. Doty,et al.  Olfactory dysfunction in parkinsonism , 1988, Neurology.

[143]  J. D. Perry,et al.  Using Activities of Daily Living Assessments to Measure the Effectiveness of Vitamin D Supplements in Elderly Long-Stay Patients , 1987 .

[144]  R. Cohen,et al.  Do vitamin D supplements improve the physical capabilities of elderly hospital patients? , 1985, Age and ageing.

[145]  J. Haddad,et al.  COMPARISON OF ORAL 25-HYDROXYCHOLECALCIFEROL, VITAMIN D, AND ULTRAVIOLET LIGHT AS DETERMINANTS OF CIRCULATING 25-HYDROXYVITAMIN D , 1977, The Lancet.

[146]  C. I. Reed,et al.  The treatment of hay fever and asthma with viosterol of high potency , 1934 .

[147]  R. Bouillon Extra-Skeletal Effects of Vitamin D. , 2018, Frontiers of hormone research.

[148]  N. Scarmeas,et al.  Vitamin D and cognition: an update of the current evidence. , 2014, Journal of Alzheimer's disease : JAD.

[149]  D. B. Teplowc,et al.  25-Dihydroxyvitamin D 3 and Resolvin D 1 Retune the Balance between Amyloid-Phagocytosis and Inflammation in Alzheimer ’ s Disease Patients , 2013 .

[150]  T. Montine,et al.  Memory, mood, and vitamin D in persons with Parkinson's disease. , 2013, Journal of Parkinson's disease.

[151]  J. Ringman,et al.  1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. , 2013, Journal of Alzheimer's disease : JAD.

[152]  M. Stein,et al.  A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[153]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[154]  K. Abel,et al.  1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. , 2009, Journal of Alzheimer's disease : JAD.

[155]  J. Jansson,et al.  A 7-Year Follow-up , 2005 .

[156]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[157]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[158]  D. Feldman,et al.  1,25-Dihydroxyvitamin D3 Induction of Nerve Growth Factor in L929 Mouse Fibroblasts: Effect of Vitamin D Receptor Regulation and Potency of Vitamin D3 Analogs1. , 1997, Endocrinology.

[159]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[160]  E. Glaser The randomized clinical trial. , 1972, The New England journal of medicine.